Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-06-06

FDA Approved: LABETALOL HYDROCHLORIDE — Supplemental Application (Advagen Pharma Ltd)

View source ↗

Summary

FDA approves Advagen Pharma Ltd's supplemental application for labetalol hydrochloride (generic), updating the product's regulatory status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Labetalol Hydrochloride (Labetalol hydrochloride)

Snippet

SUPPL AP for LABETALOL HYDROCHLORIDE (LABETALOL HYDROCHLORIDE)